SCHEMBL3653136

SCHEMBL3653136

CC1C=C(c2ccccc2)CCN1

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.42
HTR2C P28335 1/20 0.41
NISCH Q9Y2I1 1/20 0.39
PRCP P42785 2/20 0.35
SLC6A2 P23975 1/20 0.34
ADRA1A P35348 1/20 0.34
HTR2B P41595 1/20 0.34
SLC6A3 Q01959 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.33
F2 P00734 1/20 0.33
CCNT1 O60563 2/20 0.33
CDK9 P50750 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16434895 0.81 CCNT1 (0.41) HTR2CPRCPHTR2BRAB9ACCNT1
SCHEMBL11273226 0.79 NISCH (0.44) HTR2CNISCHGAA
SCHEMBL16272018 0.75 KDM4E (0.41) NISCHRAB9ACCNT1CDK9
Trifluoroacetic Acid SCHEMBL16422438 0.73 KDM1A (0.46) PRCPCCNT1CDK9
SCHEMBL5760094 0.70 DYRK1A (0.40)
SCHEMBL12469679 0.68 HSD17B10 (0.39) SIGMAR1HTR2CPRCPGAARAB9A
SCHEMBL11500404 0.68 ALDH1A1 (0.40) SIGMAR1HTR2CPRCPGAAF2
SCHEMBL22516534 0.67
SCHEMBL25803827 0.66
SCHEMBL4790510 0.64 NISCH (0.39) SIGMAR1HTR2CNISCHRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180327458-A1 PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES Sorbonne Université (FR) 2018-11-15 US disclosed
WO-2018148224-A1 PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) 2018-08-16 WO disclosed
EP-2741757-A1 COMPOSITIONS OF FUNCTIONAL MITOCHONDRIA AND USES THEREOF Minovia Therapeutics Ltd. (IL) 2014-06-18 EP disclosed
WO-2013035101-A1 COMPOSITIONS OF FUNCTIONAL MITOCHONDRIA AND USES THEREOF MINOVIA THERAPEUTICS LTD. (IL) 2013-03-14 WO disclosed
EP-2187892-A1 METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA Bioneris AB (SE) 2010-05-26 EP disclosed
WO-2009038533-A1 METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA BIONERIS AB (SE) 2009-03-26 WO disclosed
WO-2008143835-A1 GHRELIN PROTECTS SUBSTANTIA NIGRA DOPAMINE NEURONS YALE UNIVERSITY (US) 2008-11-27 WO disclosed
EP-1750710-A1 NEUROPROTECTIVE PROPERTIES OF DEXTROROTATORY MORPHINANS Kim, Hyoung-Chun (KR) 2007-02-14 EP disclosed
WO-2005110412-A1 NEUROPROTECTIVE PROPERTIES OF DEXTROROTATORY MORPHINANS GREEN CROSS CORP. (KR) 2005-11-24 WO disclosed
EP-1169005-A2 ASSOCIATION OF NO-SYNTHASE INHIBITOR(S) AND METABOLIC ANTIOXIDANT(S) SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-01-09 EP disclosed
WO-2000059448-A2 ASSOCIATION OF NO-SYNTHASE INHIBITOR(S) AND METABOLIC ANTIOXIDANT(S) SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2000-10-12 WO disclosed
EP-0819113-A1 BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT CENTAUR PHARMACEUTICALS, INC. (US) 1998-01-21 EP disclosed
WO-1996031462-A1 BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT CENTAUR PHARMACEUTICALS, INC. (US) 1996-10-10 WO disclosed